
The U.S. Food and Drug Administration (FDA) has cleared marketing of the Paxman Scalp Cooling System, a scalp cooling technology that was developed to reduce hair loss in breast cancer patients undergoing chemotherapy.
The approval is based on the same results presented at San Antonio Breast Cancer Symposium 2016.
This approval follows the approval of a similar device late in 2015.
The concept came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss.
“Hair loss is consistently ranked in the top five most distressing cancer chemotherapy side effects,” explains Richard Paxman, CEO.
The prevention of hair loss represents an important challenge in oncology, which affects over four million patients annually. By 2030 it is estimated it will affect over 6.7 million patients every year.
Link para a notícia: eCancer News







